Completed Clinical Trials

Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity

By April 24, 2017 No Comments


Malignant Pleural Mesothelioma

Estimated Enrollment: 11

Age Group: 18 Years and older   (Adult, Senior)

Gender: All

Study Type: Interventional

Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment

Study ID Numbers: 09-142

Study First Received: December 2, 2009

Last Updated: April 21, 2015

Estimated Primary Completion Date: July 2012


Primary Outcome Measures:

To Determine the Rate of Clinical Benefit (i.e. Rate of Complete or Partial Response Plus Stable Disease) at 16 Weeks for Patients With Malignant Mesothelioma Treated With Everolimus as Second or Third Line Therapy.

Sponsors and Collaborators:

Memorial Sloan Kettering Cancer Center|Novartis Pharmaceuticals|Dana-Farber Cancer Institute|University of Pennsylvania

Website Link:

Leave a Reply

Call Now